On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...